COMMITMENTS AND CONTINGENCIES	3 Months Ended
Sep. 30, 2026
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	COMMITMENTS AND CONTINGENCIES Legal Proceedings The Company is involved, from time to time, in litigation and other legal proceedings incidental to its business, including product liability (including asbestos-related claims), advertising, regulatory, employment, intellectual property, real estate, environmental, trade relations, securities, tax and privacy matters. The Company records accruals for loss contingencies when a loss is probable and reasonably estimable, and estimates reasonably possible losses or ranges of losses in excess of accrued amounts, when such estimates can be made. Such estimates involve significant judgment regarding future events and uncertainties, including timing of related payments, and are adjusted as appropriate. Legal defense costs are expensed as incurred. See below for the assessment of loss contingencies related to the Company's Securities Class Action and Derivative Matters and Cosmetic Talcum Powder Matters. Management believes that the outcome of all other pending litigation and legal proceedings will not have a material adverse effect on the Company’s operations or consolidated financial statements. Reasonably possible losses in excess of accrued amounts are not expected to be material. Management's assessments of the Company's pending litigation and other legal proceedings, including the stockholder derivative complaints, included in the Securities Class Action and Derivative Matters section below, and Cosmetic Talcum Powder Matters, are subject to inherent uncertainties and may change based on future developments. Securities Class Action and Derivative Matters During the fiscal 2026 fourth quarter, the parties to the securities class action litigation (alleging violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 based on alleged materially false and misleading statements) reached an agreement in principle to settle. As of June 30, 2026, the total settlement amount was funded, which includes the amounts paid by the insurance carriers. As such there are no amounts related to this matter reflected in the accompanying consolidated balance sheets as of September 30, 2026 or June 30, 2026. On August 20, 2026, the Company received final approval of the settlement amount from the Court. A minimal number of reported class members opted out of the settlement. At this time, no complaints have been filed by these members, and the Company believes it is not possible at this time to reasonably assess the outcome of any potential complaints or to estimate the loss or range of losses, if any. There is no impact to the fiscal 2027 consolidated financial statements for the securities class action litigation. Additional information relating to the securities class action litigation and related settlement is included in the Company's Annual Report on Form 10-K for the fiscal year ended June 30, 2026. Stockholder derivative complaints were filed on February 1, 2024 and March 15, 2024 in the United States District Court for the Southern District of New York against certain current and former officers and directors of the Company and were voluntarily dismissed without prejudice in April 2024. The Company subsequently received stockholder litigation demands requesting that the Board investigate similar allegations. A committee of the Board has been formed to review these demands and make recommendations, as appropriate. Two additional stockholder derivative complaints were filed on May 8, 2025 in the United States District Court for the Southern District of New York and were consolidated into a single case. Plaintiffs in that consolidated derivative action filed a consolidated amended complaint on August 21, 2026; one stockholder derivative complaint was filed on June 23, 2025 in the Supreme Court of the State of New York in Kings County; and four additional stockholder derivative complaints were filed on September 15, 2025, September 26, 2025, November 11, 2025 and November 12, 2025 in the Delaware Court of Chancery against certain current and former officers and directors, asserting claims including breach of fiduciary duty, unjust enrichment as well as claims of waste, gross mismanagement and insider trading. One of the Delaware complaints originally filed in September was voluntarily dismissed (as it was filed on behalf of an individual rather than a related trust that held Company stock) and refiled on November 11, 2025 by actual shareholders. The four Delaware stockholder derivative actions were consolidated into a single case and plaintiffs in that consolidated derivative action filed a single, consolidated complaint on August 24, 2026. An additional stockholder derivative complaint was filed on July 24, 2026 in the Delaware Court of Chancery against certain current and former officers and directors, asserting claims substantially similar to those in the other Delaware complaints; and additional stockholder derivative complaints were filed in the United States District Court for the Southern District of New York on August 14, 2026 and September 22, 2026 based on allegations similar to those in the existing complaints. The Company believes that it is not possible at this time to reasonably assess the outcome of these derivative matters or to estimate the loss or range of losses, if any. Cosmetic Talcum Powder Matters The Company has been named as a defendant in civil actions alleging that certain cosmetic talcum powder products were contaminated with asbestos. These matters generally involve multiple co-defendants. The Company stands behind the safety of its products for intended use, and the Company and its legal counsel believe that the Company has strong legal grounds to contest these cases and is challenging them vigorously. The Company cannot predict the outcome of each individual case pending against it. In fiscal 2025, in view of the number of cases pending against the Company as well as the evolution of the litigation landscape and expectations regarding future claims at that time, the Company took action from the end of August 2024 through October 2024 to mitigate a portion of its future exposure. During that period, the Company entered into agreements with certain plaintiff law firms to resolve over 200 pending matters, which was a portion of the pending matters that existed at that time, and establish a framework for resolving potential future claims brought by these plaintiff law firms from January 1, 2025 through December 31, 2029, subject to annual caps (the "Talcum litigation settlement agreements"). In connection with the Talcum litigation settlement agreements, the Company recorded a charge of $159 million in fiscal 2025, representing its best estimate of probable losses for current and potential future claims under these agreements, and as of September 30, 2026, $27 million and $63 million are recorded in Other accrued liabilities and Other noncurrent liabilities, respectively, in the accompanying consolidated balance sheet for these liabilities. Additional charges and reasonably possible losses related to these Talcum litigation settlement agreements, in excess of the initial charge have not been and are not expected to be material. Outside of the Talcum litigation settlement agreements, other claims are brought and may be brought by plaintiff firms not party to those agreements. As of September 30, 2026, there were 116 cases pending against the Company in U.S. state courts, as compared to 118 cases as of June 30, 2026. During the three months ended September 30, 2026, 27 cases were filed and 29 cases were resolved. For certain claims brought against the Company that have advanced to later stages, specific accruals are recorded as appropriate, and for the remaining pending claims, the Company estimates losses on an aggregate basis based on historical experience. While amounts recorded (outside the Talcum litigation settlement agreements) for the three months ended September 30, 2026 and 2025, respectively, to either settle cases, or accrue for probable losses, are not material, adverse outcomes on pending or future claims could be material. The Company cannot reasonably estimate the range of reasonably possible losses in excess of accrued amounts for these or future matters. The assessment of the Company’s current cases is ongoing and could change in light of the discovery of additional facts with respect to these cases not presently known to the Company, further legal analysis, or determinations by courts, juries or other finders of fact or deciders of law that vary from the Company’s evaluation of the probable liability or outcome of such cases. The number of new cases filed against the Company has increased in recent periods, consistent with broader trends in litigation involving talcum products generally, and the Company expects that the number of new cases filed against it, and the number of cases pending against it, may continue to increase in future periods. For the cosmetic talcum powder matters, the Company maintains insurance policies with limited coverage that may offset a portion of defense and settlement costs, subject to policy terms. Recoveries during the period and historically have not been material.

The Company records accruals for loss contingencies when a loss is probable and reasonably estimable, and estimates reasonably possible losses or ranges of losses in excess of accrued amounts, when such estimates can be made. Such estimates involve significant judgment regarding future events and uncertainties, including timing of related payments, and are adjusted as appropriate. Legal defense costs are expensed as incurred.

During the fiscal 2026 fourth quarter, the parties to the securities class action litigation (alleging violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 based on alleged materially false and misleading statements) reached an agreement in principle to settle. As of June 30, 2026, the total settlement amount was funded, which includes the amounts paid by the insurance carriers. As such there are no amounts related to this matter reflected in the accompanying consolidated balance sheets as of September 30, 2026 or June 30, 2026. On August 20, 2026, the Company received final approval of the settlement amount from the Court. A minimal number of reported class members opted out of the settlement. At this time, no complaints have been filed by these members, and the Company believes it is not possible at this time to reasonably assess the outcome of any potential complaints or to estimate the loss or range of losses, if any. There is no impact to the fiscal 2027 consolidated financial statements for the securities class action litigation.

Stockholder derivative complaints were filed on February 1, 2024 and March 15, 2024 in the United States District Court for the Southern District of New York against certain current and former officers and directors of the Company and were voluntarily dismissed without prejudice in April 2024. The Company subsequently received stockholder litigation demands requesting that the Board investigate similar allegations. A committee of the Board has been formed to review these demands and make recommendations, as appropriate.

Two additional stockholder derivative complaints were filed on May 8, 2025 in the United States District Court for the Southern District of New York and were consolidated into a single case. Plaintiffs in that consolidated derivative action filed a consolidated amended complaint on August 21, 2026; one stockholder derivative complaint was filed on June 23, 2025 in the Supreme Court of the State of New York in Kings County; and four additional stockholder derivative complaints were filed on September 15, 2025, September 26, 2025, November 11, 2025 and November 12, 2025 in the Delaware Court of Chancery against certain current and former officers and directors, asserting claims including breach of fiduciary duty, unjust enrichment as well as claims of waste, gross mismanagement and insider trading. One of the Delaware complaints originally filed in September was voluntarily dismissed (as it was filed on behalf of an individual rather than a related trust that held Company stock) and refiled on November 11, 2025 by actual shareholders. The four Delaware stockholder derivative actions were consolidated into a single case and plaintiffs in that consolidated derivative action filed a single, consolidated complaint on August 24, 2026. An additional stockholder derivative complaint was filed on July 24, 2026 in the Delaware Court of Chancery against certain current and former officers and directors, asserting claims substantially similar to those in the other Delaware complaints; and additional stockholder derivative complaints were filed in the United States District Court for the Southern District of New York on August 14, 2026 and September 22, 2026 based on allegations similar to those in the existing complaints.

The Company has been named as a defendant in civil actions alleging that certain cosmetic talcum powder products were contaminated with asbestos. These matters generally involve multiple co-defendants. The Company stands behind the safety of its products for intended use, and the Company and its legal counsel believe that the Company has strong legal grounds to contest these cases and is challenging them vigorously. The Company cannot predict the outcome of each individual case pending against it.

In fiscal 2025, in view of the number of cases pending against the Company as well as the evolution of the litigation landscape and expectations regarding future claims at that time, the Company took action from the end of August 2024 through October 2024 to mitigate a portion of its future exposure. During that period, the Company entered into agreements with certain plaintiff law firms to resolve over 200 pending matters, which was a portion of the pending matters that existed at that time, and establish a framework for resolving potential future claims brought by these plaintiff law firms from January 1, 2025 through December 31, 2029, subject to annual caps (the "Talcum litigation settlement agreements").

In connection with the Talcum litigation settlement agreements, the Company recorded a charge of $159 million in fiscal 2025, representing its best estimate of probable losses for current and potential future claims under these agreements, and as of September 30, 2026, $27 million and $63 million are recorded in Other accrued liabilities and Other noncurrent liabilities, respectively, in the accompanying consolidated balance sheet for these liabilities. Additional charges and reasonably possible losses related to these Talcum litigation settlement agreements, in excess of the initial charge have not been and are not expected to be material.

Outside of the Talcum litigation settlement agreements, other claims are brought and may be brought by plaintiff firms not party to those agreements. As of September 30, 2026, there were 116 cases pending against the Company in U.S. state courts, as compared to 118 cases as of June 30, 2026. During the three months ended September 30, 2026, 27 cases were filed and 29 cases were resolved. For certain claims brought against the Company that have advanced to later stages, specific accruals are recorded as appropriate, and for the remaining pending claims, the Company estimates losses on an aggregate basis based on historical experience.

While amounts recorded (outside the Talcum litigation settlement agreements) for the three months ended September 30, 2026 and 2025, respectively, to either settle cases, or accrue for probable losses, are not material, adverse outcomes on pending or future claims could be material. The Company cannot reasonably estimate the range of reasonably possible losses in excess of accrued amounts for these or future matters. The assessment of the Company’s current cases is ongoing and could change in light of the discovery of additional facts with respect to these cases not presently known to the Company, further legal analysis, or determinations by courts, juries or other finders of fact or deciders of law that vary from the Company’s evaluation of the probable liability or outcome of such cases. The number of new cases filed against the Company has increased in recent periods, consistent with broader trends in litigation involving talcum products generally, and the Company expects that the number of new cases filed against it, and the number of cases pending against it, may continue to increase in future periods.